Skip to main content

View full-text article in PMC

. 2014 May 1;18(5):341–348. doi: 10.1089/gtmb.2013.0503

Table 1.

Details of the Individual Studies Included in the Meta-Analysis

				Numbers		Case			Control
Author	Country	Ethnicity	Disease	Case	Control	Pro/Pro	Pro/Ala	Ala/Ala	Pro/Pro	Pro/Ala	Ala/Ala	Association p^a	Power (%)^b
Cao, 2012	China	East Asian	NAFLD	169	699	159	10	0	656	43	0	0.910	83.7
Yang, 2012	China	East Asian	NAFLD	436	467	406	30	0	409	58	0	0.007	85.1
Rey, 2010	Germany	European	NAFLD	263	363	206	48	9	280	77	6	0.878	70.6
Dongiovanni, 2010	Italy	European	NAFLD	202	346	166	33	3	295	50	1	0.217	64.8
Qing, 2007	China	East Asian	NAFLD	155	141	142	13	0	130	11	0	0.857	40.5
Pan, 2009	China	East Asian	RA	421	207	411	10	0	190	17	0	0.002	70.7
El-Sohenmy, 2006	China	East Asian	RA	473	400	450	23	0	374	25	1	0.241	84.0
Bowes, 2012	United Kingdom	European	PsA	5712	932	4416	1216	80	747	174	11	0.058	100
Butt, 2006	Canada	European	PsA	251	235	208	41	2	177	51	7	0.017	59.7

^{^a}

Allelic association.

^{^b}

Assuming an odds ratio of 1.5 (small effect size) at a level of significance of 0.05.

HWE, Hardy–Weinberg equilibrium; NAFLD, nonalcoholic fatty liver disease; RA, rheumatoid arthritis; PsA, psoriatic arthritis.